Resource — Bioelectric Medicine
Microcurrent Therapy
A current too small to feel — but large enough to change the cells it passes through. How microcurrent supports recovery from pain, soft-tissue injury, nerve dysfunction, and the systemic conditions that travel with hypermobility, autoimmunity, and chronic inflammation.
Important — What Microcurrent Is and Is Not
Microcurrent is not TENS. TENS uses milliamp-level currents you can feel — it gates pain signals through sensory stimulation. Microcurrent operates at microamp levels (typically 25–600 μA) — one thousand times weaker — usually below the threshold of perception. The mechanism is different. The goal is not to drown out pain. The goal is to deliver a signal small enough to mimic the cell’s own bioelectric environment and, in doing so, restore the cellular machinery underneath the symptoms.
Section 1
What Microcurrent Actually Does to a Cell
The defining experiment in the field was published in 1982. Cheng and colleagues applied direct current to rat skin tissue and measured what happened to cellular energy production. At currents between 50 and 500 microamps, ATP generation increased by up to 500 percent. Amino acid transport across the cell membrane increased. Protein synthesis accelerated. Above 1,000 μA — the threshold that defines TENS rather than microcurrent — those gains reversed. ATP production dropped. The cell was overwhelmed.
This is the basis of every clinical application that has followed. Microcurrent at the right dose delivers a metabolic signal the cell interprets as instruction to repair. The fibroblast accelerates collagen synthesis. The immune cell modulates its cytokine output. The injured nerve regains conduction efficiency. The inflamed tissue reduces its inflammatory tone. None of this requires sensation, drugs, or mechanical force — only an electrical signal small enough to fit inside the cell’s own native bandwidth.
ATP & Cellular Energy
Up to 500% increase in tissue ATP production within the therapeutic microamp window (Cheng 1982). Injured, inflamed, or chronically stressed tissue has measurably lower ATP. Microcurrent restores the energy supply that healing requires.
Inflammatory Cytokine Modulation
Reductions in IL-1, IL-6, TNF-α, and substance P have been documented after frequency-specific microcurrent treatment (McMakin 2005). The signal modulates the inflammatory environment itself.
Fibroblast & Fascial Response
Increased protein synthesis and amino acid transport accelerate collagen turnover. For fascia that has scarred, restricted, or stiffened, this provides the metabolic substrate remodeling depends on. Pairs cleanly with Hydrofascia Release™.
Nerve Conduction Support
Injured or chronically irritated nerves operate on degraded resting potentials. Microcurrent restores membrane polarization toward physiologic baseline — the foundation under most clinical responses in neuropathic pain and nerve recovery.
Section 2
Conditions Microcurrent Can Help — Ranked by Published Evidence
Microcurrent’s clinical applications span a wide range, but the evidence base behind each application is not equally strong. We have organized the list below from most rigorously researched to emerging or anecdotal — so you can calibrate expectations honestly. Patients still respond to microcurrent in the lower-evidence categories; the studies simply have not caught up yet.
01
Strong Evidence
Musculoskeletal Pain
A 2020 systematic review and meta-analysis of nine RCTs found microcurrent produced statistically significant short-term reductions in pain and disability for musculoskeletal conditions versus sham (Iijima et al., 2020, Clin Rehabil). This is the most rigorously documented application of microcurrent in current literature — neck pain, low back pain, joint pain, and post-operative pain all sit within this evidence base.
02
Strong Evidence
Sports Injuries & Muscle Damage Recovery
Multiple randomized controlled trials have documented reduced delayed-onset muscle soreness (DOMS), lower creatine kinase elevations, and faster functional recovery after eccentric exercise with microcurrent compared with placebo (Lambert et al., 2002, Med Sci Sports Exerc; Curtis et al., 2010, J Bodyw Mov Ther). For active patients, post-event athletes, and weekend warriors, microcurrent compresses the recovery window.
03
Strong Evidence
Wound Healing & Tissue Repair
Low-intensity electrical stimulation has decades of evidence for accelerating wound healing, including pressure ulcers and chronic non-healing wounds (Houghton et al., 2010, Arch Phys Med Rehabil). The mechanism is the same one Cheng documented in 1982 — accelerated ATP production and protein synthesis in the cells responsible for repair.
04
Moderate Evidence
Tendinopathy & Chronic Fascial Restriction
A comparative trial demonstrated greater pain and function gains with microcurrent than conventional physiotherapy in chronic Achilles tendinopathy (Chapman-Jones & Hill, 2002, Physiotherapy). Beyond tendons, microcurrent supports fibroblast activity and collagen turnover in chronically restricted fascia — the layer we image and intervene in with high-resolution ultrasound, Fascial Mapping®, and Hydrofascia Release™.
05
Moderate Evidence
Neuropathic Pain & Nerve Recovery
Microcurrent has been studied in diabetic peripheral neuropathy with modest but mixed RCT results (Gossrau et al., 2011, Pain Med). Clinically — particularly when paired with ultrasound-guided hydrodissection of compressed nerves — patients with chronic radiculopathy, post-surgical nerve irritation, and small-fiber neuropathy frequently report meaningful improvements that lab-controlled trials have only partially captured.
06
Moderate Evidence
Lymphedema & Tissue Edema
Small clinical studies have documented reductions in limb volume and discomfort with low-intensity electrical stimulation in secondary lymphedema, including post-surgical breast cancer lymphedema. The evidence base is still maturing, but the mechanism — improved interstitial fluid mobilization and reduced inflammatory load — is consistent with broader microcurrent biology.
07
Emerging Evidence
Fibromyalgia & Chronic Widespread Pain
McMakin’s frequency-specific microcurrent (FSM) cohort study in 54 fibromyalgia patients with cervical trauma documented substantial reductions in pain and in IL-1, IL-6, TNF-α, and substance P (McMakin et al., 2005, J Bodyw Mov Ther). The data are uncontrolled and hypothesis-generating — but the cytokine signal is mechanistically coherent with broader microcurrent biology. Clinically meaningful; not yet definitively proven in RCT.
08
Emerging Evidence
Systemic Inflammation & Mast Cell Stabilization
The strongest mechanistic signal here is the cytokine modulation documented by McMakin (2005). Direct human RCTs of microcurrent for mast cell activation syndrome do not yet exist — but our hypermobile and MCAS-prone patients consistently report reductions in flushing, histaminic symptoms, and inflammatory flare frequency during a microcurrent course. This indication is best understood as mechanistically plausible and clinically promising, not yet established by controlled trial. Related work: our Hypermobility & EDS Clinic and Folate-Dependent Hypermobility Syndrome protocol.
09
Emerging Evidence
Dysmenorrhea & Heavy Menstrual Flow
The strongest evidence in this domain comes from the related TENS/interferential literature, where RCTs have demonstrated meaningful reductions in primary dysmenorrhea pain (Tugay et al., 2007, Pain Med). Microcurrent-specific RCTs for menstrual symptoms are sparse — but the mechanism (autonomic and uterine inflammatory modulation) is consistent. Clinically, we see particular benefit in our hypermobile patients with overlapping pelvic floor dysfunction and inflammatory features.
10
Limited / Anecdotal
Autoimmune Disorders
This is the most cautious end of the page. Peer-reviewed RCTs of sub-sensory microcurrent for specifically defined autoimmune conditions — rheumatoid arthritis, lupus, Hashimoto’s, multiple sclerosis, psoriasis — do not currently exist. What exists is a body of case reports, FSM clinical textbook experience, and the indirect cytokine data discussed above. For patients with autoimmune diagnoses we discuss microcurrent as an adjunct with mechanistic plausibility, not as a primary or proven therapy, and we do so explicitly. The honest answer is “we have seen patients benefit; the trial evidence has not caught up; you should know both.”
A note on the negative trials
The literature is not uniformly positive. Koopman et al. (2009) failed to show benefit over sham for chronic nonspecific low back pain in a small RCT. Microcurrent dose, waveform, frequency, and patient selection vary widely across studies — and the difference between effective and ineffective treatment often comes down to those parameters. We tell you what the literature actually says, including where it disagrees.
Section 3
How We Use Microcurrent at The Fascia Institute
Microcurrent is rarely a stand-alone therapy in our New Orleans clinic. It is layered into existing treatment arcs — alongside ultrasound-guided prolotherapy, Hydrofascia Release™, and physical therapy. The combination is what produces durable change. Microcurrent buys the cellular substrate (ATP, protein synthesis, reduced inflammation) that the structural interventions then build on.
Patients in our Hypermobility & EDS Clinic protocol frequently incorporate microcurrent for the systemic and inflammatory components of their presentation — the layer that PT and structural injection medicine cannot reach. For those patients, microcurrent often pairs with our Folate-Dependent Hypermobility metabolic protocol and Genomics Performance Screening.
Treatment courses typically begin as a series. Some patients respond within the first one or two sessions; others require six to twelve sessions before the cumulative effect becomes obvious. We re-evaluate at structured intervals and adjust frequency, dose, and pairing modalities based on response.
Clinical Perspective
A Note from Dr. Jacques Courseault
“Microcurrent occupies an unusual position in our practice. The mechanism — Cheng’s ATP work and the cytokine modulation that followed — is mechanistically clean and reproducible at the cellular level. The clinical evidence for pain, sports recovery, and wound healing is solid. The clinical evidence for fibromyalgia, mast cell activation, autoimmune presentations, and dysmenorrhea is largely observational, often impressive in individual cases, and unevenly captured by the trial literature.”
“We tell our patients what the data say, where the data are silent, and where we have nonetheless seen consistent clinical results. That candor is the only honest way to introduce a modality with this kind of evidence gradient — and it is how we hope every clinic would introduce it.”
— Jacques Courseault, MD
The Fascia Institute and Treatment Center®, New Orleans
Research Foundation
Published Literature Cited on This Page
Cheng N, Van Hoof H, Bockx E, et al. The effects of electric currents on ATP generation, protein synthesis, and membrane transport in rat skin. Clin Orthop Relat Res. 1982;(171):264–272. — Foundational mechanism paper documenting up to 500% increase in ATP within the microamp therapeutic window. View on PubMed →
Iijima H, Eguchi R, Aoyama T, Takahashi M. Effectiveness of microcurrent therapy for treating pain and disability in adults with musculoskeletal pain: a systematic review and meta-analysis. Clin Rehabil. 2020;34(11):1378–1394. — Meta-analysis of nine RCTs demonstrating significant short-term reductions in pain and disability vs. sham. View on PubMed →
Lambert MI, Marcus P, Burgess T, Noakes TD. Electro-membrane microcurrent therapy reduces signs and symptoms of muscle damage. Med Sci Sports Exerc. 2002;34(4):602–607. — RCT showing reduced DOMS and creatine kinase elevation after eccentric exercise. View on PubMed →
Curtis D, Fallows S, Morris M, McMakin C. The efficacy of frequency specific microcurrent therapy on delayed onset muscle soreness. J Bodyw Mov Ther. 2010;14(3):272–279. — Placebo-controlled trial of FSM for post-eccentric-exercise recovery. View on PubMed →
Houghton PE, Campbell KE, Fraser CH, et al. Electrical stimulation therapy increases the rate of healing of pressure ulcers in community-dwelling people with spinal cord injury. Arch Phys Med Rehabil. 2010;91(5):669–678. — Accelerated wound healing with low-intensity electrical stimulation. View on PubMed →
Chapman-Jones D, Hill D. Novel microcurrent treatment is more effective than conventional therapy for chronic Achilles tendinopathy: randomised comparative trial. Physiotherapy. 2002;88(8):471–480. — Microcurrent vs. conventional physiotherapy in chronic Achilles tendinopathy. View Article →
Gossrau G, Wähner M, Kuschke M, et al. Microcurrent transcutaneous electric nerve stimulation in painful diabetic neuropathy: a randomized placebo-controlled study. Pain Med. 2011;12(6):953–960. — Mixed RCT result in painful diabetic neuropathy; modest benefit on some outcomes. View on PubMed →
McMakin CR, Gregory WM, Phillips TM. Cytokine changes with microcurrent treatment of fibromyalgia associated with cervical spine trauma. J Bodyw Mov Ther. 2005;9(3):169–176. — Observational cohort showing reductions in IL-1, IL-6, TNF-α, and substance P after frequency-specific microcurrent. View on PubMed →
Tugay N, Akbayrak T, Demirtürk F, et al. Effectiveness of transcutaneous electrical nerve stimulation and interferential current in primary dysmenorrhea. Pain Med. 2007;8(4):295–300. — RCT showing meaningful reductions in primary dysmenorrhea pain with electrical stimulation. View on PubMed →
Koopman JSHA, Vrinten DH, van Wijck AJM. Efficacy of microcurrent therapy in the treatment of chronic nonspecific back pain: a pilot study. Clin J Pain. 2009;25(6):495–499. — Honest counter-evidence: microcurrent did not outperform sham in this small chronic LBP trial. View on PubMed →
For Home Use — Clinical Grade
The Micro-Sport Device
For patients who need ongoing microcurrent support between clinic visits — or who travel frequently — we recommend the Micro-Sport device. It is a clinical-grade unit designed for sustained home use, with the dose, waveform, and frequency parameters required to deliver the therapeutic effects discussed on this page.
Investment: $2,995. We recommend a clinical evaluation first to determine whether ownership is appropriate for your treatment plan.
Begin a Microcurrent Course
Cellular medicine, delivered with honest evidence.
Every microcurrent course at The Fascia Institute begins with a physician evaluation — a conversation about what you are dealing with, what the imaging shows, and what the literature actually supports for your specific condition. From there we build a plan you can verify, measure, and trust.
Request an Evaluation
Hypermobility & EDS Clinic
The Fascia Institute and Treatment Center® · New Orleans, Louisiana
Serving New Orleans, Metairie, the North Shore, Baton Rouge, and the greater Gulf South.
This page is intended as a patient education resource and does not constitute medical advice. All treatment decisions should be made in consultation with your physician. Evidence-strength labels reflect our reading of the current peer-reviewed literature as of May 2026 and are subject to change as new research emerges.